For manufacture and supply of Azacitidine Injection for the U.S market
Panacea Biotec has entered into a tripartite agreement with Natco Pharma ('Natco') and Breckenridge Pharmaceutical Inc. ('Breckenridge') for the manufacture and supply of Azacitidine Injection for the U.S. market under Breckenridge's already-approved ANDA. Azacitidine is a generic equivalent of Vidaza, which is marketed by Celgene Corporation, U.S.As per the terms of the agreement, Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec's facility located at Baddi, Himachal Pradesh, India. Panacea Biotec will be responsible for manufacture and supply of the product, which will be marketed, sold and distributed by Breckenridge in the U.S.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content